129 related articles for article (PubMed ID: 2566650)
1. Characterization of [3H]quipazine binding to 5-hydroxytryptamine3 receptors in rat brain membranes.
Milburn CM; Peroutka SJ
J Neurochem; 1989 Jun; 52(6):1787-92. PubMed ID: 2566650
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.
Sharif NA; Wong EH; Loury DN; Stefanich E; Michel AD; Eglen RM; Whiting RL
Br J Pharmacol; 1991 Apr; 102(4):919-25. PubMed ID: 1830236
[TBL] [Abstract][Full Text] [Related]
3. Labelling of 5-hydroxytryptamine3 receptors with a novel 5-HT3 receptor ligand, [3H]RS-42358-197.
Wong EH; Bonhaus DW; Wu I; Stefanich E; Eglen RM
J Neurochem; 1993 Mar; 60(3):921-30. PubMed ID: 8436978
[TBL] [Abstract][Full Text] [Related]
4. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
[TBL] [Abstract][Full Text] [Related]
5. Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
Barnes JM; Barnes NM
Biochem Pharmacol; 1993 May; 45(10):2155-8. PubMed ID: 8390263
[TBL] [Abstract][Full Text] [Related]
6. Solubilisation of the 5-hydroxytryptamine3 receptor from pooled rat cortical and hippocampal membranes.
McKernan RM; Quirk K; Jackson RG; Ragan CI
J Neurochem; 1990 Mar; 54(3):924-30. PubMed ID: 2303819
[TBL] [Abstract][Full Text] [Related]
7. [3H]zacopride binding to 5-hydroxytryptamine3 sites on partially purified rabbit enteric neuronal membranes.
Gordon JC; Barefoot DS; Sarbin NS; Pinkus LM
J Pharmacol Exp Ther; 1989 Dec; 251(3):962-8. PubMed ID: 2600824
[TBL] [Abstract][Full Text] [Related]
8. Agonist interactions with 5-HT3 receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligands.
Barnes JM; Barnes NM; Costall B; Jagger SM; Naylor RJ; Robertson DW; Roe SY
Br J Pharmacol; 1992 Feb; 105(2):500-4. PubMed ID: 1559139
[TBL] [Abstract][Full Text] [Related]
9. Species variations in 5-HT3 recognition sites labeled by 3H-quipazine in the central nervous system.
Peroutka SJ
Naunyn Schmiedebergs Arch Pharmacol; 1988 Nov; 338(5):472-5. PubMed ID: 3244388
[TBL] [Abstract][Full Text] [Related]
10. Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding.
Hoyer D; Neijt HC
Mol Pharmacol; 1988 Mar; 33(3):303-9. PubMed ID: 3352595
[TBL] [Abstract][Full Text] [Related]
11. Improvement of 5-HT3 receptor binding assay: enhancement of specific [3H]quipazine binding with Triton X-100-treated membranes from rat cortex.
Une T; Furukawa K; Komiya M
Jpn J Pharmacol; 1991 Oct; 57(2):197-203. PubMed ID: 1812298
[TBL] [Abstract][Full Text] [Related]
12. Autoradiography of [3H]quipazine in rodent brain.
Perry DC
Eur J Pharmacol; 1990 Oct; 187(1):75-85. PubMed ID: 2272355
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of 5-hydroxytryptamine3 receptors in murine brain and ileum using the novel radioligand [3H]RS-42358-197: evidence for receptor heterogeneity.
Bonhaus DW; Wong EH; Stefanich E; Kunysz EA; Eglen RM
J Neurochem; 1993 Nov; 61(5):1927-32. PubMed ID: 8229003
[TBL] [Abstract][Full Text] [Related]
14. Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells.
Bolaños FJ; Schechter LE; Miquel MC; Emerit MB; Rumigny JF; Hamon M; Gozlan H
Biochem Pharmacol; 1990 Oct; 40(7):1541-50. PubMed ID: 2222509
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of 5-HT3 recognition sites in membranes of NG 108-15 neuroblastoma-glioma cells with [3H]ICS 205-930.
Neijt HC; Karpf A; Schoeffter P; Engel G; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):493-9. PubMed ID: 3412489
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissues.
Kidd FJ; Levy JC; Nielsen M; Hamon M; Gozlan H
Eur J Pharmacol; 1993 Sep; 247(1):45-56. PubMed ID: 8258360
[TBL] [Abstract][Full Text] [Related]
17. Characterization of [3H]meta-chlorophenylbiguanide binding to 5-HT3 receptors in N1E-115 neuroblastoma cells.
Lummis SC; Sepúlveda MI; Kilpatrick GJ; Baker J
Eur J Pharmacol; 1993 Oct; 243(1):7-11. PubMed ID: 8253126
[TBL] [Abstract][Full Text] [Related]
18. [3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes.
Peroutka SJ; Hamik A
Eur J Pharmacol; 1988 Mar; 148(2):297-9. PubMed ID: 3378579
[No Abstract] [Full Text] [Related]
19. '[3H]quipazine' degradation products label 5-HT uptake sites.
Schmidt AW; Hurt SD; Peroutka SJ
Eur J Pharmacol; 1989 Nov; 171(1):141-3. PubMed ID: 2533080
[No Abstract] [Full Text] [Related]
20. Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat.
Barnes JM; Barnes NM; Champaneria S; Costall B; Naylor RJ
Neuropharmacology; 1990 Nov; 29(11):1037-45. PubMed ID: 2087255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
